Indolent Lymphoma - Pipeline Review, H2 2012 New Report
Indolent Lymphoma - Pipeline Review, H2 2012, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Indolent Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Indolent Lymphoma. Indolent Lymphoma - Pipeline Review, Half Year is built using data and information sourced from databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites...
View full press release